Exosome Therapeutics Market Size Worth $ 1,487.55 Million By 2034 | CAGR: 20.63%

The global exosome therapeutics market size is expected to reach USD 1,487.55 million by 2034, exhibiting a CAGR of 20.63% during the forecast period, according to a new study by Polaris Market Research & Consulting, Inc. The report “Exosome Therapeutics Market Size, Share, Trends, & Industry Analysis Report By Source, By Application, By Route of Administration, By End Use, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Exosomes are nano-sized vesicles secreted by cells that transport proteins, lipids, and nucleic acids between cells. Their natural role in intercellular communication and low immunogenicity are drawing drug developers seeking alternatives to living-cell therapies. Biotechnology companies are translating this biology into investigational medicines, with candidates moving from laboratory research into human trials across a widening set of indications. This shift from research use toward regulated drug products is shaping the commercial outlook of the exosome therapeutics market.

Late-stage clinical and regulatory progress is drawing greater attention from investors and developers. The FDA's decision on Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy, scheduled for November 22, 2026, could mark the first approval of a therapy with an exosome-mediated mechanism of action. Meanwhile, Direct Biologics continues to enroll patients in its Phase 3 study of ExoFlo for acute respiratory distress syndrome. Developers are also engineering exosomes to carry gene-editing tools and therapeutic proteins, opening new avenues in genetic and inflammatory diseases.

Analysts at Polaris Market Research & Consulting, Inc. view the outcome of the Deramiocel review as the defining near-term event for the category, as it is likely to set the manufacturing and potency benchmarks that follow-on programs must meet. Over the forecast period, value is expected to shift toward engineered exosome platforms and scalable GMP production, favoring companies that pair delivery technology with manufacturing readiness.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Exosome Therapeutics Market Report

Exosome Therapeutics Market Report Highlights

• The mesenchymal stem cell derived segment captured 46.38 % of revenue in 2025, while the cardiosphere derived cell segment is set to post the fastest CAGR of 23.72% through 2034, as the FDA decision on Deramiocel approaches.
• North America held a 41.72 % share in 2025, led by US-based late-stage programs, while Asia Pacific is anticipated to expand at the fastest CAGR of 25.47%, backed by hospital-led studies in China and South Korea's regenerative medicine framework.
• A few global key market players include Aegle Therapeutics Corporation; Aruna Bio, Inc.; Capricor Therapeutics, Inc.; Direct Biologics, LLC; EXO Biologics SA; Evox Therapeutics Ltd.; ExoCoBio Inc.; ILIAS Biologics Inc.; Kimera Labs Inc.; NurExone Biologic Inc.; and ReNeuron Group plc.

Polaris Market Research & Consulting, Inc. has segmented the exosome therapeutics market report based on source, application, route of administration, end use, and region:

By Source Outlook (Revenue, USD Million, 2021–2034)

• Mesenchymal Stem Cell Derived
• Cardiosphere Derived Cell
• Other/Engineered

By Application Outlook (Revenue, USD Million, 2021–2034)

• Cardiovascular & Muscular Disease
• Respiratory & Acute Care
• Infectious Disease & Vaccinology
• Neurodegenerative Disease
• Others

By Route of Administration Outlook (Revenue, USD Million, 2021–2034)

• Intravenous
• Inhaled/Localized
• Others

By End Use Outlook (Revenue, USD Million, 2021–2034)

• Hospitals & Specialty Treatment Centers
• Contract Development & Manufacturing Organizations
• Others

By Regional Outlook (Revenue, USD Million, 2021–2034)

• North America
  • US
  • Canada

Europe

• • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa